Geode Capital Management LLC Has $13.05 Million Position in Immunome, Inc. (NASDAQ:IMNM)

Geode Capital Management LLC boosted its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 1.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,228,851 shares of the company’s stock after purchasing an additional 21,396 shares during the quarter. Geode Capital Management LLC owned 1.54% of Immunome worth $13,054,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in IMNM. KLP Kapitalforvaltning AS bought a new stake in Immunome in the fourth quarter valued at about $75,000. AlphaQuest LLC increased its holdings in shares of Immunome by 786,700.0% in the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after purchasing an additional 7,867 shares in the last quarter. Stoneridge Investment Partners LLC acquired a new position in shares of Immunome during the fourth quarter valued at $123,000. Teacher Retirement System of Texas bought a new stake in Immunome during the 4th quarter worth about $124,000. Finally, Intech Investment Management LLC raised its holdings in Immunome by 26.5% during the 4th quarter. Intech Investment Management LLC now owns 18,961 shares of the company’s stock worth $201,000 after purchasing an additional 3,974 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on IMNM. Guggenheim lowered their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. Wedbush restated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research report on Thursday, March 20th. Lifesci Capital initiated coverage on Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 target price on the stock. Stephens restated an “overweight” rating and set a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th. Finally, Lake Street Capital assumed coverage on shares of Immunome in a research report on Wednesday, April 2nd. They issued a “buy” rating and a $23.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $25.14.

Insider Activity at Immunome

In other Immunome news, CEO Clay B. Siegall acquired 150,000 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were acquired at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the transaction, the chief executive officer now directly owns 669,636 shares in the company, valued at $5,189,679. This trade represents a 28.87 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CTO Philip Tsai purchased 12,300 shares of the stock in a transaction on Monday, March 24th. The stock was acquired at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the completion of the purchase, the chief technology officer now directly owns 33,300 shares in the company, valued at approximately $280,386. The trade was a 58.57 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 306,400 shares of company stock valued at $2,322,995. 8.60% of the stock is owned by insiders.

Immunome Stock Performance

Shares of IMNM stock opened at $8.00 on Tuesday. The company has a market capitalization of $695.61 million, a P/E ratio of -0.99 and a beta of 2.05. Immunome, Inc. has a 52 week low of $5.15 and a 52 week high of $16.81. The company’s 50 day moving average price is $8.15 and its two-hundred day moving average price is $10.32.

Immunome (NASDAQ:IMNM) last announced its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The company had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. Analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.